Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cadefrecitinib · GLPG-3667

Small molecule · developed by Lakefront Biotherapeutics NV

Phase 2 Most advanced trial (none active)
LKFT Developer
3 Registered trials

What is Cadefrecitinib?

Cadefrecitinib (GLPG3667) is an investigational agent studied in healthy participants and in dermatomyositis, given orally, as a capsule, and as an intravenous infusion of a radiolabeled microdose.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
GLPG-3667
Drug type
Small molecule
Therapy area
Dermatology, Musculoskeletal, Neurology
Developer
Lakefront Biotherapeutics NV (LKFT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
NKX4HH6CWK

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05695950 Phase 2 Dermatomyositis Completed LKFT
NCT05335447 Phase 1 Healthy Completed LKFT
NCT04097938 Phase 1 Healthy Completed LKFT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

DermatomyositisHealthy

More from Lakefront Biotherapeutics NV

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the LKFT page.

Follow LKFT, the company behind Cadefrecitinib

See LKFT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LKFT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.